Neonatal drug company charts course to commercialization
On the heels of winning an eight-year quest for approval of a drug to help preterm infants breathe, an East Coast drug developer outlined a $12 million to $13 million commercialization plan. Discovery Labs (NASDAQ:DSCO) secured approval from the U.S. Food and Drug Administration for Surfaxin, the first synthetic surfactant to treat respiratory distress syndrome […]